Use of laser photomodulation in the evolution of oral mucositis associated to cyclophosphamide, methotrexate, 5-fluouracil - CMF in 5 fluouracil + adriamycin + cyclophosphamide - FAC chemotherapy protocols in patients with breast cancer

2013 ◽  
Author(s):  
Maria de Fátima Lima Ferreira ◽  
Fabiola Bastos de Carvalho ◽  
Susana C. P. S. de Oliveira ◽  
Juliana S. C. Monteiro ◽  
Gustavo M. P. Santos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oral Mucositis ◽  
Fac Chemotherapy

scholarly journals The role of hormonal ovarian ablation in adjuvant treatment of premenopausal breast cancer

2011 ◽  
Vol 139 (5-6) ◽  
pp. 339-346
Author(s):  
Zafir Murtezani ◽  
Zora Neskovic-Konstantinovic ◽  
Natasa Stanisavljevic ◽  
Vladimir Kovcin
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Steroid Receptors ◽  
Premenopausal Women ◽  
Small Sample ◽  
Malignant Tumours ◽  
Group 13 ◽  
Ovarian Ablation ◽  
Fac Chemotherapy ◽  
Lh Rh

Introduction. Breast cancer is the most frequent malignant disease in women with about 25% compared to all malignant tumours. Chemotherapy, antiestrogen and ovarian ablation/ supression present effective adjuvant approach for premenopausal women diagnosed with hormonal depended, operable breast cancer. Objective. To evaluate benefits of combined chemo/hormonal therapy that is undutiful, but optimal application has not yet been clearly determined. Methods. Thirty-six women were divided into three therapy groups. The first group (13 women) was treated with six cycles of adjuvant FAC chemotherapy followed by regular check-ups; the second group (13 women) after six cycles of adjuvant FAC chemotherapy continued treatment with a two-year application of goserelin given by subcutaneous injections (FAC-Z); the third group (10 women), after six cycles of adjuvant FAC chemotherapy continued with once per month application of gorselin for two years and a daily application of 20 mg tamoxifen for five years (FAC-Z-T). The length of overall disease free period and survival were analyzed in all three groups. Results. The benefit of LH-RH analogues in premenopausal women with hormone-dependent breast cancer was found to be low, and probably limited to smaller subgroups of patients, possibly such as those with either both steroid receptors positive (ER and PR) or those with an extremely high level of steroid receptors. In our paper, analyses of such subgroups could not been performed due to a small sample of patients. The effect of therapy is better in patients, who developed amenorrhoea, regardless of the type of later hormonal therapy. Conclusion. Ovarial ablation, whatever the method, should be probably applied as early as possible within the treatment of early breast cancer, especially in patients in whom chemotherapy induced amenorrhoea is not expected, i.e. in very young female patients.

scholarly journals Characterization of the patient with chemotherapy-induced oral mucositis / Caracterização do paciente com mucosite oral induzida por quimioterapia / Caracterización de la paciente con mucositis oral inducida por quimioterapia

2015 ◽  
Vol 4 (1) ◽  
pp. 26
Author(s):  
Jaylinne Ribeiro Morais ◽  
Thiago Rêgo Vanderley ◽  
Rômulo Diego Monte Soares ◽  
Augusto Everton Dias Castro ◽  
Sarah Nilkece Mesquita Araújo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gastrointestinal Tract ◽  
Oral Mucositis ◽  
Private Practice ◽  
Exploratory Study ◽  
Age Groups ◽  
Female Age ◽  
Common Cancer ◽  
Private Health Facility

Objectives: To characterize cancer patients with oral mucositis treated at a private health facility. Methodology: An exploratory study with descriptive quantitative approach developed in 87 patients in a private practice oncology in Teresina, PI, from August 2011 to January 2012. Results: Findings indicated the prevalence of oral mucositis in males and in the age groups 40-59 years and more than 60. The most common cancer diagnoses were gastrointestinal tract and breast cancer, the treatments focused on chemoradiation, determining predominantly grades I and II of oral mucositis. Overall, mucositis had low discontinuation of cancer treatment and nursing procedures were mainly observed when patients had mucositis grade I. Conclusion: Patients are mostly female, age 40-59 years, with an education 11 or more years. Have an income 2-4 minimum wages and the most frequent types of cancers were the gastrointestinal tract and breast cancer, respectively. Descriptors: Stomatitis. Oncology. Chemotherapy. Nursing 

Laser therapy for radio-induced oral mucositis and skin dermatitis: Oral medicine, radiotherapy and oncology shared experience from the University of Trieste.

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 213-213
Author(s):  
Margherita Gobbo ◽  
Alessandra Guglielmi ◽  
Giulia Ottaviani ◽  
Katia Rupel ◽  
Serena Zacchigna ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Laser Therapy ◽  
Oral Mucositis ◽  
Anal Carcinoma ◽  
Life Quality ◽  
Breast Cancer Patients ◽  
Anal Lesions ◽  
The University

213 Background: Oral mucositis (OM) and dermatitis (RD) are serious side effects of radiotherapy (RT), often leading to its suspension, need for analgesics and enteral/parenteral nutrition. Laser-therapy is becoming a recommended option for mucosal lesions and has also been tested for skin affections. This prospective study investigates the effect of Laser-therapy (HPLT) on RT-induced OM and proposes an off-label use of HPLT to treat RD in breast-cancer patients and in RT-treated anal-carcinoma patients Methods: 53 cancer patients, during/after RT and/or chemotherapy, affected by OM, were treated with HPLT during 4 consecutive days (970nm, 2,5W, 35-6000Hz, 240s). Assessment of OM (WHO-SCALE: Grading objective Scale), pain (VAS: Visual Analogue Scale), functional ability, subjective parameters, site/severity of OM were recorded weekly for 21 days. 27 breast-cancer patients and 2 anal-carcinoma patients affected by RD were treated by HPLT every other day for 2 weeks (970nm/660nm, 2-1000Hz, 6W, 480s) and monitored weekly for one month for grade, discomfort, itching and bleeding. Results: Regarding OM, regressive improvement of WHO- SCALE from day 7 on, and of VAS from day 2 on (p < 0.000) was registered. All patients’ functional capacity improved on day 4 (p < 0.05). All subjective parameters improved on day 14 (p < 0.001) except voice, which improved on day 21 (p < 0.000). Ulcerations’ dimension and erythema’s severity decreased in all sites (p < 0.05). Regarding breast and anal RD, after 6 HPLT’s sessions, complete and progressive resolution of pain, bleeding and itching was registered (p < 0.002). All patients referred maximum satisfaction for receiving HPLT. Conclusions: Regardless of OM grade/site and of kind/site of tumor, HPLT was effective in healing OM. Moreover, HPLT resulted an innovative and highly effective therapy for RD, both in breast and anal lesions. To establish an effective treatment strategy for OM and RD is of paramount importance to improve life-quality of patients but can also be beneficial for the continuation of cancer therapy. Consequently, HPLT may become integral part of everyday-practice in the management of RT adverse effects.

scholarly journals Oxidative stress parameters in women with breast cancer undergoing neoadjuvant chemotherapy and treated with nutraceutical doses of oral glutamine

2011 ◽  
Vol 26 (suppl 1) ◽  
pp. 82-87 ◽  
Author(s):  
José Wilson Mourão de Farias ◽  
Flavia Siqueira Furtado ◽  
Sergio Botelho Guimarães ◽  
Antônio Ribeiro da Silva Filho ◽  
Paulo Roberto Leitão de Vasconcelos
Keyword(s):  
Breast Cancer ◽  
Oxidative Stress ◽  
Neoadjuvant Chemotherapy ◽  
Milk Protein ◽  
Normal Breast ◽  
Drug Infusion ◽  
Oxidative Stress Parameters ◽  
Tumor Tissues ◽  
Fac Chemotherapy ◽  
Post Menopause

PURPOSE: To evaluate the effects of oral administration of GLN on the oxidative stress in women with breast cancer undergoing neoadjuvant FAC chemotherapy (5 fluouracil 500 mg/m²+Doxorubicin 50 mg/m²+Cyclophosphamide 500 mg/m² body surface area). METHODS: Twenty women (mean age: 51.7 years) with breast ductal carcinomas classified as T3 or T4 were included in the study, regardless of pre or post menopause status. Sachets containing glutamine 15g ("A") or milk protein 15g ("B") were prepared by a registered pharmacist. Allocation of patients was made by software program. Patients who received sachets labeled "A" were included in G1 group. The remaining patients, treated with the preparation labeled "B", were included in group G2. Sachets contents were blended in 150 ml of drinking water, and were given daily to each patient during the entire course of neoadjuvant chemotherapy. Peripheral blood samples were collected in the first day of each of the three cycles of chemotherapy before drug infusion. Tumor and normal breast samples were collected at the end of Patey´s surgical procedure. Samples were analysed for GSH and TBARS contents. RESULTS: TBARS and GSH values were not different in breast healthy and tumor tissues nor blood when comparing control (G-2) and glutamine-treated (G-1) patients. Also, no significant differences were found in TBARS and GSH levels comparing different timepoints within the same group. CONCLUSION: Oral GLN (15g/kg/day) offers no protection against systemic or local oxidative stress in women with breast Ca undergoing neoadjuvant chemotherapy (FAC).

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer

2007 ◽  
Vol 108 (2) ◽  
pp. 183-190 ◽  
Author(s):  
Fabrice Andre ◽  
Chafika Mazouni ◽  
Cornelia Liedtke ◽  
Shu-Wan Kau ◽  
Debby Frye ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Her2 Expression ◽  
Fac Chemotherapy

scholarly journals Evaluation of the use of Orasol Plus®, A Mouthwash Based on Plant Extracts, in Mucositis in Patients with Breast Cancer Receiving Chemotherapy

2020 ◽  
Vol 3 (1) ◽  
Keyword(s):  
Breast Cancer ◽  
Oral Mucositis ◽  
Target Therapy ◽  
Preventive Measure ◽  
Strong Impact ◽  
Breast Cancer Patients ◽  
Breast Cancer Chemotherapy ◽  
Chemotherapy Drugs ◽  
Treatment Dose ◽  
Other Substances

Breast cancer is the first and most common cancer in women and represents the leading cause of female cancer death. To treat cancer, the treatment that is giving more results is the conventional poly-chemotherapy with numerous other substances that have specific action, called target therapy. During the treatment of breast cancer, chemotherapy drugs lead to the frequent detection of side effects, first of all, the Oral Mucositis. Oral mucositis (OM) is a common in cancer therapy, found in a percentage of 15-40%, and cause severe sequelae and strong impact on a patient’s quality of life (QoL), health care costs, and ultimately outcome by influencing the treatment dose. There are some and limited therapeutic options to help reduce the severity of OM. Our study evaluated the action of a mix of natural supplements (swallowable solution, Orasol plus®, for reduction of mucositis during chemotherapy, with Lapacho (Tabebuia Avellanedae Lorentz ex Griseb.), Camellia Sinensis L. Kuntze, Calendula Officinalis L, Malva Sylvestris L, Sisymbrium Officinale (L) Scop, Plantago Major L e Propoli) in 15 breast cancer patients under treatment with chemotherapy and target therapy. No patients had stopped the treatment because of mucositis. From 11 patients that have mucositis during treatment, 5 had complete remission at the and of the first cycle in the 4 patients who took Orasol Plus®, as a preventive measure, none developed mucositis during antiblastic treatments. The data of our study depose for the effectiveness of Orasol Plus® in the treatment of oral mucositis, in patients undergoing chemotherapy for breast cancer. They need a larger study to insert Orasol Plus® in a standardized pathway in the treatment of oral mucositis during chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document